Attendee search 

Guoqian Medical Technology (Suzhou) Co., Ltd. was registered and established in Suzhou High-tech Zone in 2017.

Guoqian Medical has two business platforms: Guoqian Venture Capital and Guoqian Medical Technology Innovation Research Institute.

Guoqian Venture Capital is a professional and market-oriented venture capital institution that focuses on equity investment in early innovation and entrepreneurship projects in the fields of medical devices, in vitro diagnostic reagents and biotechnology. Focusing on high-end scientific and technological talents with Chinese major talent engineering experts as the core, they seek high-quality investment targets during the transformation of scientific and technological achievements, the introduction of technological projects, the evaluation of innovative and entrepreneurial projects, and the landing of innovative and entrepreneurial projects.

Guoqian Medical Technology Innovation Research Institute is committed to cultivating cutting-edge technologies and projects in the domestic medical device industry, and providing it with multi-faceted technologies, policies, talents, industrialization and markets through direct investment, entrepreneurial services, and scientific and technological achievement transformation services. Integration of services and resources to create an innovative platform for national technological innovation and industrial integration and empowerment. At the same time, it has also become an enabling platform for post-investment enterprises of Guoqian Fund. By creating industrial clusters and industrial ecology, it will provide post-investment management, post-investment services, and post-investment empowerment to post-investment enterprises.

Based on the business philosophy of “achieving the dreams of others”, Guoqian Medical uses market-oriented and specialized equity investment funds to create industrial agglomeration and industrial ecology; it empowers post-investment enterprises by creating industrial agglomeration and industrial ecology. The two platforms complement each other, and strive to build a medical device industry cluster and ecosystem in Suzhou High-tech Zone in 10 years, becoming one of the main promoters of the domestic medical device industry.

JIANGBEI NEW AREA IS THE 13rd national new area，and 1st in jiangsu province.

A Biopharma company, looking for license in opportunities.

VC focused on healthcare industry

PE/VC firm

TF Capital focuses on investment in the life sciences industry, primarily investing in early stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.

3E Bioventures Capital is dedicated to investing in cutting-edge life sciences and biomedical technologies, with a focus on breakthrough first-in-class therapies and disruptive cross-disciplinary innovations in medical devices and diagnostics.

3E Bioventures takes on a science-driven, entrepreneur-friendly investment philosophy by working closely with companies and research institutions to develop drugs or products that have strong unmet medical needs. With offices in Beijing, Shanghai, and the San Francisco Bay Area, 3E Bioventures leverages its experience, capabilities, and network to help companies tap into markets and resources across the Pacific and advance with greater speed and capital efficiency.

The motto of 3E Bioventures Capital is captured in its name 3E: Expertise, Efficiency, Execution.

Founded in 2016 with over $800 million assets under management, Terra Magnum Capital Partners ("TMCP" or "the firm") is a China-focused private equity firm specialized in both direct investments and fund investments.

PE/VC firm

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.